Spanish price discounts have silver lining for generic medicines industry
This article was originally published in Scrip
Government spending on pharmaceuticals is continuing to fall in Spain, thanks to price discounts introduced last year. But the situation appears to be a double edged sword for the generic medicines industry, which has seen its volume share of the market increase while its value share remains stagnant.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.